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Abstract
Problem: To describe immunohistochemical features encountered in ovarian fibrothecoma with
correlation to clinical presentation and surgical management.
Method of study: A female age 75 presented for evaluation of melena. The patient reported total
abdominal hysterectomy and removal of both ovaries 40 years earlier.
Results: CA-125 was normal and there was no evidence of hyperestrogen effect. Pelvic CT
revealed a partially calcified 7 cm pelvic mass without adenopathy or ascites; ultrasound was
confirmatory. Endoscopy identified three benign intestinal tubular adenomas. Following
laparoscopic excision of the pelvic tumor immunohistochemichal analysis of the mass showed
negative staining for keratin, S100 protein, inhibin, calretinin, melan A, smooth muscle actin, CD34,
CD117, and desmin. The tissue was positive for vimentin, however.
Conclusion: Ovarian fibrothecomas represent an ovarian stromal neoplasm developing in a wide
spectrum of clinical settings. Particularly if oophorectomy is stated to have been performed remote
from the time of index presentation, the status of the ovaries must be considered whenever pelvic
pathology is encountered. We describe a calcified ovarian fibrothecoma identified during
gastroenterology investigation and confirmed immunohistochemically via high amplitude vimentin
signal.
Background
Stromal tumors of the ovary include thecoma and
fibroma, yet as differentiation between these two types
may be difficult the term fibrothecoma has emerged in
recognition of the similar immunohistochemical features
present in both. The exact incidence of fibrothecoma is
unknown, although they have been described as rare ovar-
ian neoplasms [1]. Here we present an unusual clinical
manifestation of calcified ovarian fibrothecoma in the
absence of ascites, arising from a residual ovary intention-
ally conserved at laparotomy 40 years earlier.
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A non-smoking 75 year old Caucasian female presented
for gastroenterology evaluation due to rectal bleeding. She
had mild essential hypertension well controlled on
diltiazem, did not smoke, and had no other medical com-
plaint. She reported intermittent oral use of aspirin, 81
mg/d. In 1966, she underwent total abdominal hysterec-
tomy "when both ovaries were removed". At the time of
our evaluation, the patient used supplemental estrogen
occasionally but was uncertain when this commenced.
Her only other surgery was an uncomplicated laparo-
scopic cholecystectomy performed in 1996.
The patient's BMI was 26. Vital signs and physical exam
were normal although a heme positive stool was noted.
Abdominal CT showed no significant abnormality,
although pelvic CT revealed a 7 cm partially calcified mass
at the upper pelvic inlet, indistinguishable from bowel
[Figure 1]. Ultrasound of this lesion confirmed a 74 × 45
× 49 mm heterogeneous (partially echogenic) mass in the
upper right pelvis.
Serum electrolytes were unremarkable except for BUN and
Cr at 20 mg/dl and 1.1 mg/dl, respectively. Hemoglobin
was 11.8 g/dl. Serum hCG, CEA, and CA-125 were all nor-
mal.
Surgical management
A 12 mm umbilical port was placed along with two acces-
sory ports (both 5 mm caliber), one each at the left upper
and lower quadrants. Extensive abdominal adhesions
were encountered and lysed with blunt dissection and
harmonic scalpel. Eventually an approximately 7 cm
smooth, white glistening mass could be seen in the right
aspect of the pelvis [Figure 2]. The mass was attached lat-
erally to the right pelvic sidewall; these connections were
secured with 10 mm endosurgical clips and then divided
to free the tumor. Survey of abdomen and pelvis revealed
no other gross abnormality. Estimated blood loss was ~50
ml and the patient was discharged home the same after-
noon in excellent condition.
Immunohistochemistry protocol
Formalin-fixed tumor sections embedded in paraffin were
exposed to 10 mmol/L citrate buffer (pH 6.0), followed by
incubation with 1:50 dilution of monoclonal mouse anti-
vimentin (M0725, DakoCytomation, Carpinteria, CA,
USA) using 20 min heat-induced epitope retrieval in
DakoCytomation Target Retrieval solution (S3308) × 30
min incubation at room temperature with primary anti-
body. Negative control was 1:50 dilution mouse IgG1
(X0931) which was run simultaneously. Complexes were
visualized via DAKO LSAB+/HRP kit (K0679) and auto-
mated stainer platform. The specimen demonstrated pos-
itive vimentin staining for mesenchymal spindle and
round cells, consistent with benign ovarian stromal neo-
plasm [Figure 3]. The full panel consisted of antibodies to
keratin, S100, inhibin, calretinin, melanoma associated
marker "Melan A", smooth muscle actin, CD34, CD117
and desmin, but none returned a positive result [Table 1].
Discussion
We report an unusual case of partially calcified ovarian
fibrothecoma without ascites in an elderly female report-
ing previous oophorectomy and complaining of melena.
For this patient, her gastrointestinal bleeding was deter-
Right ovarian fibrothecoma (F) and pedicle (P) at laparoscopyF ure 2
Right ovarian fibrothecoma (F) and pedicle (P) at laparos-
copy. Calcified nodule is shown superiorly (arrow).
F
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Pelvic CT demonstrating 7 cm fibrothecoma (F) in the upper right pelvis and associated calci cation (arrow)Figure 1
Pelvic CT demonstrating 7 cm fibrothecoma (F) in the upper 
right pelvis and associated calcification (arrow). No ascites or 
bowel dilation is present. Uterus and left ovary are surgically 
absent in this 75 year-old patient.
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during the work-up associated with this lesion that suspi-
cion was raised regarding a 7 cm calcified right pelvic
mass. While this mass did appear benign intraoperatively,
metal endosurgical clips were deployed to assist subse-
quent radiographic localization of tumor site in the event
adjuvant radiotherapy was indicated. Excision of the
tumor at laparoscopy confirmed its ovarian origin, and
immunohistochemical labeling was performed to charac-
terize it more fully as a benign fibrothecoma.
Other investigators have commented on the protean
nature of ovarian tumors in this group that may occur in
the setting of edema [2], elevated CA-125 [3,4], and preg-
nancy [5]. While immunohistochemical features of this
neoplasm have been described previously [6-8], the the-
coma-fibroma group of ovarian stromal tumors repre-
sents a spectrum of lesions in which clear distinctions
between various entities are difficult to define6. However,
tumor calcification and low serum CA-125 are infrequent
findings.
One finding that proved useful in finalizing the diagnosis
for our patient was the high affinity for vimentin staining,
characteristic of ovarian fibrothecoma [2]. Vimentin is a
57 kD intermediate filament protein forming the cytoskel-
eton of vertebrate cells. The protein was initially thought
to be preferentially retained in malignant mesenchymal
tissues, although coexpression of intermediate filaments
(particularly cytokeratin and vimentin) was subsequently
shown to exist in many benign lesions. Accordingly,
application of multiple antibodies is recommended to
formulate a diagnosis with sufficient precision, as demon-
strated in our case. Indeed for this calcified ovarian
fibrothecoma, vimentin was the only positive immuno-
histochemical marker registered from a panel of ten anti-
bodies.
The impact of patient recall error while obtaining the sur-
gical history also warrants comment. A variant of residual
ovary syndrome, the problem begins when the patient is
unaware of an ovary intentionally conserved at surgery.
The ovary subsequently develops a pathologic process or
causes symptoms necessitating its removal in a second
operation [9]. Not surprisingly, this is more likely among
subjects of advanced age who may have never known (or
forgotten) important details of an operation performed
long ago and for which no written record can be obtained.
Our patient had believed that she had no ovaries for 40
years, a "fact" dutifully reported to multiple physicians
over time. Could awareness of her retained single ovary
have alerted this patient's caregivers to the presence of
ovarian fibrothecoma sooner? Certainly when hysterec-
tomy-oophorectomy is stated to have been performed
remote from the time of index presentation, an in situ
ovary should still be considered whenever pelvic pathol-
ogy is encountered.
Table 1: Immunohistochemical characteristics observed in calcified ovarian fibrothecoma without ascites.
Assay/antibody Tissue marker for Result
Vimentin Vimentin, intermediate filaments, mesenchymal cells +
CAM 5.2 Keratin: 39, 43, 48, 50, 50.6 kD -
S100 S100 Protein, nerve sheath tumor, melanoma, chondrocyte -
Inhibin Sex cord stromal tumors, adrenal (cortical) tumors -
Calretinin Ca++ binding protein, mesothelial cells, sex cord stromal tumors -
Melan A Melanoma associated marker, adrenal (cortical) tumors -
SMA Smooth muscle actin, myofibroblasts, myoepithelial cells -
CD34 Endothelial and stem cells, GI stromal tumor -
CD117 Myeloid and mast cells, GI stromal tumor (c-kit) -
Desmin Muscle, desmoplastic small round cell tumor -
Microscopic features of ovarian fibrothecoma include round and spindle shaped nuclei without atypia r myxoid changeFigure 3
Microscopic features of ovarian fibrothecoma include round 
and spindle shaped nuclei without atypia or myxoid change. 
No mitotic figures were observed. Standard H&E (H) and 
vimentin stain (V), 40× magnification.
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